Margaret M. Tarpey

Corporate Officer/Principal bei University of Pittsburgh

Consumer Services

Health Technology

Profil

Margaret M.
Tarpey is the founder of Complexa, Inc. (founded in 2008).
She is currently a Professor at the University of Pittsburgh (since 2013).
Dr. Tarpey's education includes an undergraduate degree from the University of California, Riverside and a graduate degree from the University of California San Diego.

Aktive Positionen von Margaret M. Tarpey

Unternehmen	Position	Beginn
University of Pittsburgh	Corporate Officer/Principal	-

Alle aktiven Positionen von Margaret M. Tarpey

Ehemalige bekannte Positionen von Margaret M. Tarpey

Unternehmen	Position	Ende
Complexa, Inc. Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.	Gründer	-

Sehen Sie sich die Erfahrung von Margaret M. Tarpey im Detail an

Ausbildung von Margaret M. Tarpey

University of California, Riverside	Undergraduate Degree
University of California San Diego	Graduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Margaret M. Tarpey im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
Complexa, Inc. Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.	Health Technology